OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Public ClinicalTrials.gov record NCT00076089. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Study identification
- NCT ID
- NCT00076089
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 1,100 participants
Conditions and interventions
Conditions
Interventions
- Roflumilast Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2003
- Primary completion
- Nov 30, 2005
- Completion
- Nov 30, 2005
- Last update posted
- Dec 1, 2016
2003 – 2005
United States locations
- U.S. sites
- 35
- U.S. states
- 35
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ALTANA Pharma | Cities in Alabama | Alabama | — | — |
| ALTANA Pharma | Cities in Arizona | Arizona | — | — |
| ALTANA Pharma | Cities in Arkansas | Arkansas | — | — |
| ALTANA Pharma | Cities in California | California | — | — |
| ALTANA Pharma | Cities in Colorado | Colorado | — | — |
| ALTANA Pharma | Cities in Connecticut | Connecticut | — | — |
| ALTANA Pharma | Cities in Florida | Florida | — | — |
| ALTANA Pharma | Cities in Georgia | Georgia | — | — |
| ALTANA Pharma | Cities in Illionois | Illinois | — | — |
| ALTANA Pharma | Cities in Iowa | Iowa | — | — |
| ALTANA Pharma | Cities in Kentucky | Kentucky | — | — |
| ALTANA Pharma | Cities in Louisiana | Louisiana | — | — |
| ALTANA Pharma | Cities in Massachusetts | Massachusetts | — | — |
| ALTANA Pharma | Cities in Minnesota | Minnesota | — | — |
| ALTANA Pharma | Cities in Missouri | Missouri | — | — |
| ALTANA Pharma | Cities in Montana | Montana | — | — |
| ALTANA Pharma | Cities in Nebraska | Nebraska | — | — |
| ALTANA Pharma | Cities in Nevada | Nevada | — | — |
| ALTANA Pharma | Cities in New Hampshire | New Hampshire | — | — |
| ALTANA Pharma | Cities in New Jersey | New Jersey | — | — |
| ALTANA Pharma | Cities in New York | New York | — | — |
| ALTANA Pharma | Cities in North Carolina | North Carolina | — | — |
| ALTANA Pharma | Cities in Ohio | Ohio | — | — |
| ALTANA Pharma | Cities in Oklahoma | Oklahoma | — | — |
| ALTANA Pharma | Cities in Oregon | Oregon | — | — |
| ALTANA Pharma | Cities in Pennsylvania | Pennsylvania | — | — |
| ALTANA Pharma | Cities in Rhode Island | Rhode Island | — | — |
| ALTANA Pharma | Cities in South Carolina | South Carolina | — | — |
| ALTANA Pharma | Cities in Tennessee | Tennessee | — | — |
| ALTANA Pharma | Cities in Texas | Texas | — | — |
| ALTANA Pharma | Cities in Utah | Utah | — | — |
| ALTANA Pharma | Cities in Vermont | Vermont | — | — |
| ALTANA Pharma | Cities in Virginia | Virginia | — | — |
| ALTANA Pharma | Cities in West Virginia | West Virginia | — | — |
| ALTANA Pharma | Cities in Wisconsin | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00076089, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 1, 2016 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00076089 live on ClinicalTrials.gov.